Skip to main content

Smith Christopher M's Form 4 filing

Ortho Clinical Diagnostics Holdings plc (OCDX) · filed Jan 5, 2022

Accession no.
0001209191-22-001678
Filed
Jan 5, 2022
Trade date
Jan 3, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.11M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Smith Christopher MCIK 0001436707Director, Officer (Chairman and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Ordinary Shares, $0.00001 par valueMOption exerciseAcquired+100,000$12.56+$1,256,000467,360Direct
Jan 3, 2022Ordinary Shares, $0.00001 par valueSSaleDisposed−100,000$21.10F2,F3−$2,110,000367,360Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Ordinary Shares, $0.00001 par valueMOption exerciseDisposed−100,000$0.00$0935,710Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sales price for the price increments ranging from $21.0000 to $21.4000

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)